2081.pdf

Oryginał 
Scientific Opinion on the substantiation of health claims related to adenosine triphosphate (ATP) and maintenance of normal muscle function (ID 1946) pursuant to Article 13(1) of Regulation (EC) No 1924/2006[sup]1[/sup] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2, 3 European Food Safety Authority (EFSA), Parma, Italy
Słowa kluczowe: Adenosine triphosphate (ATP)   health claims   muscle  
ID:    1946  
Produkty: Adenozynotrójfosforan  

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claim is adenosine triphosphate (ATP). ATP consists of adenosine and three phosphate groups (triphosphate). ATP can be synthesised in human tissues and occurs widely in nature, including foods. ATP is measurable in foods by established methods.
The Panel considers that the food constituent, adenosine triphosphate (ATP), which is the subject of the health claim, is sufficiently characterised.

2. Znaczenie oświadczenia dla zdrowia człowieka

The claimed effect is “muscular and nervous system”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to normal muscle function.
The Panel considers that maintenance of normal muscle function is a beneficial physiological effect.

3. Naukowe uzasadnienia wpływu na zdrowie człowieka - Utrzymanie prawidłowego funkcjonowania mięśni

Among the references provided were narrative reviews and animal and in vitro studies which addressed outcomes unrelated to the claimed effect, such as the effect of ATP in various clinical applications as well as the effect of ATP on respiratory parameters in cardiac tissue and the action on purinergic receptors. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claimed effect.
In a randomised, double-blind study (Jordan et al., 2004), the effects of ATP supplementation on indices of anaerobic capacity and muscular strength were studied in 27 healthy males who performed resistance training 2-4 times per week. Subjects received either a daily dose of 150 or 225 mg of enterically coated ATP, or placebo, for 14 days. Tests of muscular strength and of peak anaerobic
power, anaerobic fatigue and total anaerobic capacity were performed 7 days before (baseline), at day 1 and at day 14 of the supplementation phase. Whole blood or plasma ATP concentrations did not differ between treatment groups. No significant differences between groups for any parameter of muscular strength or anaerobic power were observed.
In a double-blind, randomised, placebo-controlled study, the effect of ATP administration (90 mg/day) was investigated in 162 men and women aged 18 to 55 years with sub-acute low back pain of category 1 or 2, i.e. radiating no farther than the intergluteal fold or the knee, with no neurological signs and lasting from 4 to 12 weeks (Bannwarth et al., 2005). In both placebo and intervention groups, the score on the Roland-Morris Disability Questionnaire (French validated version) decreased during the trial and at endpoint (day 30) the score between the groups and the changes from baseline were similar.
The same authors reported on another intervention study in which patients with sub-acute low back pain were randomised to either receive some advice to remain active even in case of persistence of pain, or the same advice plus administration of ATP (90 mg/day) for 90 days (Rossignol et al., 2005). The Panel notes that this study was uncontrolled and non-blinded, and considers that no conclusions can be drawn from this reference for the scientific substantiation of the claimed effect.
In weighing the evidence, the Panel took into account that the data presented did not show an effect of ATP on normal muscle function.
The Panel concludes that a cause and effect relationship has not been established between the consumption of adenosine triphosphate (ATP) and maintenance of normal muscle function.

Wnioski

On the basis of the data presented, the Panel concludes that:
The food constituent, adenosine triphosphate (ATP), which is the subject of the health claim, is sufficiently characterised.
The claimed effect is “muscular and nervous system”. The target population is assumed to be the general population. Maintenance of normal muscle function is a beneficial physiological effect.
A cause and effect relationship has not been established between the consumption of adenosine triphosphate (ATP) and maintenance of normal muscle function.